Kucukoner, MehmetIsikdogan, AbdurrahmanArpaci, ErkanBilici, MehmetUncu, DoganCetin, BulentDane, Faysal2024-04-242024-04-2420120172-6390https://doi.org/10.5754/hge11709https://hdl.handle.net/11468/20305Background/Aims: The aims of this study were to report the clinical outcomes of adjuvant chemo-radiotherapy after curative resection in 637 patients with gastric cancer. Methodology: The retrospective analysis included 637 patients with resectable gastric cancer and stage IB-IV (MO) from 8 medical centers between 2003 and 2010. The patients were treated with 5FU-leucovorin and radiotherapy according to Schema for INT-0116. Results: Of the 637 patients, the median of overall survival (OS) was 43.7 months and relapse free survival (RFS) was 36.6 months. OS rates were 84%, 45%, 40% while RFS rates were 81%, 45% and 35% at 1, 3 and 5-years, respectively. Hematological and gastro-intestinal toxicities (grade 1-4) were observed in 35% and 36.5% of patients, respectively. In univariate analysis, according to the Lauren classification, tumor grade, T stage, N stage, type of operation (total gastrectomy or subtotal) and surgery resection margin (R0 or R1) were found as prognostic factors on RFS and OS (p<0.05). In multivariate analysis, T stage, N stage and surgical margins were found as effective factors on OS. T stage, N stage and Lauren classification were factors affecting RFS. Conclusions: Adjuvant chemo-radiotherapy after curative resection of gastric cancer was feasible, with acceptable toxicities in the Turkish population.eninfo:eu-repo/semantics/closedAccessAdjuvant ChemoradiationGastricCancerAdjuvant Chemoradiation for Gastric Cancer: Multicentric Study of the Anatolian Society of Medical OncologyAdjuvant Chemoradiation for Gastric Cancer: Multicentric Study of the Anatolian Society of Medical OncologyArticle5911923432347WOS:0003126892000692238930110.5754/hge11709Q3